Mr. Ahmad Doroudian reports

BETTERLIFE PHARMA ANNOUNCES APPOINTMENT OF DOUG DRYSDALE AS EXECUTIVE CHAIRMAN AND DIRECTOR

Betterlife Pharma Inc. has appointed Doug Drysdale, currently Betterlife's corporate adviser and formerly chief executive officer of Cybin Inc., as executive chairman and director.

At Cybin, Mr. Drysdale led the company's strategy and team buildout, taking it from molecule inception to phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental health care through numerous speaking engagements, panel participation and media interviews.

"We are delighted to welcome Doug to our board of directors. His proven global leadership, underscored by a track record of executing multiple successful transactions across diverse markets and therapeutic indications, brings a depth of strategic insight and operational expertise that will meaningfully strengthen Betterlife", said Ahmad Doroudian, CEO of Betterlife. "Doug's experience navigating complex deal environments and scaling opportunities across jurisdictions will be invaluable as we continue to advance our growth strategy and create long-term shareholder value."

Mr. Drysdale commented: "I am thrilled to join Betterlife as executive chairman and director. Having led Cybin from molecule inception to phase 3 trials in just three years, I look forward to bringing that same execution focus and global transaction expertise to accelerate Betterlife's growth strategy. Together with the team, we will continue to advance innovative therapies that target neurological disorders and deliver long-term value for patients and shareholders alike."

Pursuant to the appointment of Mr. Drysdale as executive chairman, the company has agreed to grant Mr. Drysdale stock options to purchase 3.5 million common shares of Betterlife, with an exercise price of 6.5 cents, monthly vesting over 24 months and a 10-year term.

About Betterlife Pharma Inc.

Betterlife Pharma is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development, and it is unique in that it is unregulated and therefore can be self-administered. Betterlife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of various neurological disorders, until around 2042.

Betterlife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

We seek Safe Harbor.